nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.11.2010

Neuro-ophthalmologic Complications and Manifestations of Upper and Lower Motor Neuron Facial Paresis

verfasst von: M. Tariq Bhatti, Jade S. Schiffman, Anastas F. Pass, Rosa A. Tang

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

The facial nerve (cranial nerve VII) courses a long pathway beginning in the precentral gyrus and ending at the facial muscles, lacrimal and salivary glands, and structures of the inner ear. Lesions along this pathway, clinically divided into upper and lower motor neuron lesions, present with unique characteristics that assist the physician in identifying the lesion site. The sequelae particularly of peripheral CN VII palsies, may result in significant and chronic damage to the cornea that may be challenging for the physician and patient.

Anderson CA, Sandberg E, Filley CM, et al.: One and one-half syndrome with supranuclear facial weakness: magnetic resonance imaging localization. Arch Neurol 1999, 56(12):1509–1511.CrossRefPubMed

Gilden DH: Clinical practice. Bell’s palsy. N Engl J Med 2004, 351(13):1323–1331.CrossRefPubMed

Rahman I, Sadiq SA: Ophthalmic management of facial nerve palsy: a review. Surv Ophthalmol 2007, 52(2):121–144.CrossRefPubMed

Razfar A, Afifi AM, Manders EK, et al.: Ocular outcomes after gold weight placement and facial nerve resection. Otolaryngol Head Neck Surg 2009, 140(1):82–85.CrossRefPubMed

Hoffman WY: Reanimation of the paralyzed face. Otolaryngol Clin North Am 1992, 25(3):649–667.PubMed

Conley J, May M: Perspectives in facial reanimation. In The Facial Nerve. edn 2. Edited by May M, Schaitkin BM. New York: Thieme Medical Publishers; 2000:551–570.

van de Graaf RC, IJpma FF: Remarks on the early history of Bell’s palsy. Eur Arch Otorhinolaryngol 2008, 265(11):1433–1434.CrossRefPubMed

Schirm J, Mulkens PS: Bell’s palsy and herpes simplex virus. APMIS 1997, 105(11):815–823.CrossRefPubMed

Devriese PP, Schumacher T, Scheide A, et al.: Incidence, prognosis and recovery of Bell’s palsy. A survey of about 1,000 patients (1974–1983). Clin Otolaryngol Allied Sci 1990, 15(1):15–27.CrossRefPubMed

10.

Hauser WA, Karnes WE, Annis J, Kurland LT: Incidence and prognosis of Bell’s palsy in the population of Rochester, Minnesota. Mayo Clin Proc 1971, 46(4):258–264.PubMed

11.

Adour KK, Byl FM, Hilsinger RL Jr, et al: The true nature of Bell’s palsy: analysis of 1,000 consecutive patients. Laryngoscope 1978, 88(5):787–801.PubMed

12.

Yanagihara N, Mori H, Kozawa T, et al.: Bell’s palsy. Nonrecurrent v recurrent and unilateral v bilateral. Arch Otolaryngol 1984, 110(6):374–377.PubMed

13.

Gilden D: Treatment of Bell’s palsy—the pendulum has swung back to steroids alone. Lancet Neurol 2008, 7(11):976–977.CrossRefPubMed

14.

House JW, Brackmann DE: Facial nerve grading system. Otolaryngol Head Neck Surg 1985, 93(2):146–147.PubMed

15.

Schaitkin BM, May M: Reporting recovery of facial function. In The Facial Nerve. edn 2. Edited by May M, Schaitkin BM. New York: Thieme Medical Publishers; 2000:275–294.

16.

de Ru JA, van Benthem PP, Hordijk GJ: Arguments favouring the pharmacotherapy of Bells’ palsy [in Dutch]. Ned Tijdschr Geneeskd 2005, 149(26):1454.PubMed

17.

Kang TS, Vrabec JT, Giddings N, Terris DJ: Facial nerve grading systems (1985–2002): beyond the House-Brackmann scale. Otol Neurotol 2002, 23(5):767–771.CrossRefPubMed

18.

Salinas RA, Alvarez G, Ferreira J: Corticosteroids for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2004, CD001942.

19.

Allen D, Dunn L: Aciclovir or valaciclovir for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2004, CD001869.

20.

Sullivan FM, Swan IR, Donnan PT, et al.: Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med 2007, 357(16):1598–1607.CrossRefPubMed

21.

•• Engström M, Berg T, Stjernquist-Desatnik A, et al.: Prednisolone and valaciclovir in Bell’s palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008, 7(11):993–1000. This study included 839 BP patients treated within 72 h of onset of symptoms in a double-blind protocol. It found that patients receiving prednisolone alone achieved a significantly shorter time to full recovery compared with those receiving combination therapy. At 6 months, full recovery was achieved in 71% (n = 150) of the prednisolone/placebo group (P < 0.003), 58% (n = 120) of the valacyclovir/placebo group (P < 0.0001), 72% (n = 149) of the prednisolone/valacyclovir group (P < 0.0001), and 62% (n = 127) of the double-placebo group (P < 0.0001). Further, use of antiviral treatment did not provide any additional benefit. CrossRefPubMed

22.

Minnerop M, Herbst M, Fimmers R, et al: Bell’s palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. J Neurol 2008, 255(11):1726–1730.CrossRefPubMed

23.

Hato N, Yamada H, Kohno H, et al.: Valacyclovir and prednisolone treatment for Bell’s palsy: a multicenter, randomized, placebo-controlled study. Otol Neurotol 2007, 28(3):408–413.CrossRefPubMed

24.

Kawaguchi K, Inamura H, Abe Y, et al: Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell’s palsy. Laryngoscope 2007, 117(1):147–156.CrossRefPubMed

25.

Yeo SG, Lee YC, Park DC, Cha CI: Acyclovir plus steroid vs steroid alone in the treatment of Bell’s palsy. Am J Otolaryngol 2008, 29(3):163–166.CrossRefPubMed

26.

• de Almeida JR, Al Khabori M, Guyatt GH, et al.: Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA 2009, 302(9):985–993. The authors performed a meta-analysis of 18 clinical trials totaling 2,786 patients with BP to determine the effect of corticosteroids and antiviral agents on the risk of unsatisfactory facial recovery. Corticosteroids were found to reduce the risk of an unsatisfactory recovery outcome, whereas antiviral agents were found to have no beneficial effect. The combination of corticosteroids and antiviral agents had a borderline effect in reducing the risk of an unsatisfactory recovery outcome. CrossRefPubMed

27.

• Goudakos JK, Markou KD: Corticosteroids vs corticosteroids plus antiviral agents in the treatment of Bell palsy: a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg 2009, 135(6):558–564. Five randomized controlled studies published from 1996 to 2007 totaling 738 patients were analyzed. The authors found no benefit from adding an antiviral agent to corticosteroids in increasing the recovery rate of FNP in patients with BP. CrossRefPubMed

28.

Hato N, Matsumoto S, Kisaki H, et al.: Efficacy of early treatment of Bell’s palsy with oral acyclovir and prednisolone. Otol Neurotol 2003, 24(6):948–951.CrossRefPubMed

29.

Gilden DH, Tyler KL: Bell’s palsy—is glucocorticoid treatment enough? N Engl J Med 2007, 357(16):1653–1655.CrossRefPubMed

30.

Murakami S, Mizobuchi M, Nakashiro Y, et al.: Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996, 124(1 Pt 1):27–30.PubMed

31.

Madhok V, Falk G, Fahey T, Sullivan FM: Prescribe prednisolone alone for Bell’s palsy diagnosed within 72 h of symptom onset. BMJ 2009, 338:b255.CrossRefPubMed

32.

Tyler KL: Prednisolone—but not antiviral drugs—improves outcome in patients with Bell’s palsy. Nat Clin Pract Neurol 2009, 5(2):74–75.CrossRefPubMed

33.

Davenport RJ, Sullivan F, Smith B, et al.: Treatment for Bell’s palsy. Lancet 2008, 372(9645):1219–1220; author reply 1220–1211.CrossRefPubMed

34.

Lockhart P, Daly F, Pitkethly M, et al.: Antiviral treatment for Bell’s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2009, CD001869.

35.

Frueh BR, Preston RA, Musch DC: Facial nerve injury and hemifacial spasm. Am J Ophthalmol 1990, 110(4):421–423.PubMed

36.

Jordan DR, Patrinely JR, Anderson RL, Thiese SM: Essential blepharospasm and related dystonias. Surv Ophthalmol 1989, 34(2):123–132.CrossRefPubMed

37.

Cramer H, Otto K: Meige’s syndrome: clinical findings and therapeutic results in 50 patients. Neuroophthalmology 1986, 6(1):3–15.CrossRef

38.

Koutsis G, Kokotis P, Sarrigiannis P, et al.: Spastic paretic hemifacial contracture in multiple sclerosis: a neglected clinical and EMG entity. Mult Scler 2008, 14(7):927–932.CrossRefPubMed

39.

Andermann F, Lloydsmith DL, Gloor P, et al.: Facial myokimia in multiple sclerosis. Brain 1961, 84(1):31.CrossRef

40.

Tenser RB, Corbett JJ: Myokymia and facial contraction in brain stem glioma. An electromyographic study. Arch Neurol 1974, 30(6):425–427.PubMed

41.

Waybright EA, Gutmann L, Chou SM: Facial myokymia. Pathological features. Arch Neurol 1979, 36(4):244–245.PubMed

42.

Bettoni L, Bortone E, Ghizzoni P, Lechi A: Myokymia in the course of Bell’s palsy. An electromyographic study. J Neurol Sci 1988, 84(1):69–76.CrossRefPubMed

43.

Brackmann DE, Fetterman BL: Cranial nerve VII. In Textbook of Clinical Neurology. edn. 3. Edited by Goetz CG. Oxford, UK: Saunders Elsevier; 2003:1392.

Titel: Neuro-ophthalmologic Complications and Manifestations of Upper and Lower Motor Neuron Facial Paresis
verfasst von: M. Tariq Bhatti
Jade S. Schiffman
Anastas F. Pass
Rosa A. Tang
Publikationsdatum: 01.11.2010
Verlag: Current Science Inc.
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 6/2010
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-010-0143-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

A Review of Conduction Aphasia

Neurologic and Muscular Complications of the 2009 Influenza A (H1N1) Pandemic

Is the Magnesium Era for Aneurysmal Subarachnoid Hemorrhage Over?

Neurologic Consequences of the Immune Reconstitution Inflammatory Syndrome (IRIS)

Neuro-Ophthalmologic Complications of Syringobulbia